Description

DISCLAIMER This is an information request only. This request is issued solely for information and planning purposes – it does not constitute a Request for Proposal (RFP) or a promise to issue an RFP in the future. Solicitations are not available currently. This notice does not constitute a commitment by the United States Government to contract for any supply or service whatsoever. Purpose: The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) invites you to collaborate on a critical mission: to develop a field-forward, threat-agnostic metagenomic next-generation sequencing (mNGS) capability for rapid identification of traditional, novel, emerging, and engineered infectious disease agents. This initiative seeks to address a critical gap in the current diagnostic portfolio by enabling hypothesis-free identification of pathogens that may be undetectable by standard targeted assays. This RFI is your opportunity to help shape the future of military medical diagnostics and contribute directly to the health, readiness, and resilience of our Armed Forces in diverse operational environments. This initiative is a critical component of a Medical Readiness and Response capability. Potential technologies will directly support Formation Based Layered Protection. By enabling early and accurate characterization of pathogens, agnostic metagenomic next-generation sequencing (mNGS) clinical diagnostics capability will help the Joint Force avoid being understood by disrupting adversary capabilities to identify, locate, and target. By enabling appropriate and timely treatment, they will help the warfighter avoid being hit and ensure they can survive if hit or attacked to sustain and regenerate combat power. Requested Information of Interest: CPE CBRND is conducting essential market research for a new initiative dedicated to identifying and advancing mature, portable, and integrated mNGS systems for clinical diagnostics. The program is focused on overcoming technical and regulatory hurdles currently preventing deployment of mNGS as a routine clinical diagnostic tool, particularly in resource-limited or austere settings. Unlike targeted assays, mNGS offers comprehensive and unbiased detection of pathogens (i.e., viral, bacterial, fungal, and parasitic) from a human clinical sample (e.g. blood, respiratory sample, or other minimally invasive sample types). This capability is essential for diagnosing infections of unknown origin, traditional, novel or genetically modified threats, providing molecular data for outbreak investigations, and enabling informed decisions by Department of War (DoW) leadership. We are seeking collaboration with innovative industry partners who are developing cutting-edge, end-to-end solutions that address the following critical challenges: Integrated "Sample-to-Answer" System : Fully-automated and ruggedized platforms that minimize manual steps from nucleic acid extraction of clinical samples an…

Place of Performance

Contracting Office

Contacts